Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) (ORCHARD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03944772
Recruitment Status : Recruiting
First Posted : May 10, 2019
Last Update Posted : July 10, 2019
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy. This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple study treatments.

Condition or disease Intervention/treatment Phase
Non-Small Cell Lung Cancer Drug: Osimertinib Drug: Savolitinib Drug: Gefitinib Drug: Necitumumab Drug: Durvalumab Drug: Carboplatin Drug: Pemetrexed Phase 2

Detailed Description:

This is an open-label, multicentre, multi-drug, biomarker-directed Phase 2 platform study in patients with advanced non-small cell lung cancer (NSCLC) harbouring an epidermal growth factor receptor (EGFR)-sensitizing mutation whose disease has progressed on first-line monotherapy with osimertinib.Treatment options for these patients are limited. Novel treatments for these patients are urgently required.

This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple study treatments.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Phase 2 platform study in patients with advanced Non-Small Lung Cancer harbouring an epidermal growth factor receptor (EGFR)-sensitizing mutation with evidence of radiological progression following first-Line osimertinib therapy. This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple study treatments. The study will be conducted in three groups (Groups A, B and C). Patient allocation to a study treatment within each group will be based on tumour molecular profile. Biomarker positive patients will be allocated to a biomarker-matched study treatment in Group A, patients without a biomarker will be allocated to a study treatment in Group B, patients who are not eligible for either of these 2 groups will be allocated to Group C (observational; patients managed in accordance with local practice).
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Biomarker-directed Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy
Actual Study Start Date : June 25, 2019
Estimated Primary Completion Date : November 11, 2022
Estimated Study Completion Date : November 11, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer
Drug Information available for: Osimertinib

Arm Intervention/treatment
Experimental: Module 1: Osimertinib + Savolitinib
The patients in this group will receive Osimertinib taken in combination with savolitinib
Drug: Osimertinib
Osimertinib given orally at 80 mg once daily
Other Name: TAGRISSO

Drug: Savolitinib
Savolitinib will be given orally once daily at 600 mg for patients with a body weight of >55 kg and 300 mg for patients with a body weight of ≤55 kg and for Japanese patients.

Experimental: Module 2: Osimertinib + Gefitinib
The patients in this group will receive Osimertinib taken in combination with Gefitinib
Drug: Osimertinib
Osimertinib given orally at 80 mg once daily
Other Name: TAGRISSO

Drug: Gefitinib
Gefitinib given orally at 250 mg once daily
Other Name: Iressa

Experimental: Module 3: Osimertinib + Necitumumab
The patients in this group will receive Osimertinib taken in combination with Necitumumab
Drug: Osimertinib
Osimertinib given orally at 80 mg once daily
Other Name: TAGRISSO

Drug: Necitumumab
Necitumumab given IV at 800 mg on Day 1 and Day 8 of every 3-week cycle
Other Name: Portrazza

Experimental: Module 4: carboplatin + pemetrexed + durvalumab)
The patients in this group will receive Platinum-containing doublet (carboplatin + pemetrexed) taken in combination with durvalumab.
Drug: Durvalumab
Durvalumab given IV at 1500 mg on Day 1 of every cycle
Other Name: IMFINZI

Drug: Carboplatin
Carboplatin given IV on Day 1 of every 21-day cycle for up to 6 cycles

Drug: Pemetrexed
Pemetrexed given IV at 500 mg/m2 body BSA on Day 1 of every cycle

No Intervention: Observational Cohort: No study drug

Patients in this group will not receive study treatment but receive further anticancer care (Standard of Care therapy or other experimental therapies) or supportive care, as clinically indicated, in accordance with local practice.

With Group C, the aim is to understand the clinical course and/or outcome for the overall clinical population after progression on first-line monotherapy with osimertinib.




Primary Outcome Measures :
  1. Objective response rate (ORR) [ Time Frame: Measured from first dose until confirmed response or progression. For each patient this is expected to be 3 months on average ]
    The percentage of patients with a confirmed investigator-assessed complete or partial response according to Response Evaluation Criteria In Solid Tumours (RECIST) 1.1. Patients will be followed up every 6 weeks (±1 week) for the first 24 weeks and every 9 weeks thereafter until RECIST 1.1 defined disease progression or cessation of study treatment (if treating beyond progression).


Secondary Outcome Measures :
  1. Progression-free survival (PFS) [ Time Frame: Measured from first dose until progression. For each patient this is expected to be 18 months on average ]
    The time from first dose until the date of objective disease progression or death (by any cause in the absence of progression). Patients will be followed up every 6 weeks (±1 week) for the first 24 weeks and every 9 weeks thereafter until RECIST (Response Evaluation Criteria In Solid Tumours)1.1 defined disease progression or cessation of study treatment (if treating beyond progression).

  2. Duration of response (DoR) [ Time Frame: Measured from response until progression. For each patient this is expected to be 15 months on average ]
    The time from the date of first response until date of disease progression or death in the absence of disease progression. Patients will be followed up every 6 weeks (±1 week) for the first 24 weeks and every 9 weeks thereafter until RECIST 1.1 defined disease progression or cessation of study treatment (if treating beyond progression).

  3. Overall survival (OS) [ Time Frame: Measured from first dose until death or final cohort data cut-off. For each patient this is expected to be 30 months on average ]
    The time from the date of the first dose of study treatment until death due to any cause.

  4. Plasma concentrations of therapeutic agents [ Time Frame: Pre-dose and 1 hour post-dose blood samples on Day 1 of Cycles 1, 3, 6 for all therapeutic agents and a sample at the 90-day safety follow up for durvalumab only. (One Cycle = 21 or 28 days, depending on treatment) ]
    Blood samples will be collected at various timepoints to evaluate the pharmacokinetics of study therapeutic agents.

  5. Incidence of Treatment-emergent adverse events (AEs) and serious adverse events (SAEs) as characterized and graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event [CTCAE] v5 [ Time Frame: Continuously from first dose to end of safety follow up after study treatment discontinuation (approximately up to 21 Months) ]
    To evaluate safety and tolerability of each study treatment



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria applicable to all study treatment modules (Groups A/B):

  • Non-Small Cell Lung Cancer (NSCLC) with the following features -

    • Locally advanced or metastatic disease (i.e., advanced NSCLC) not amenable to curative surgery or radiotherapy at study entry.
    • Histologically or cytologically confirmed adenocarcinoma of the lung harbouring EGFR mutation(s) known to be associated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) sensitivity at diagnosis.
    • Received only 1 line of therapy, with single-agent osimertinib, for advanced NSCLC, with clinical benefit as judged by investigator discretion.
    • Evidence of radiological disease progression on first-line monotherapy with osimertinib 80mg once daily.
  • Suitable for a mandatory biopsy defined as having an accessible tumour and a stable clinical condition that will allow the patient to tolerate the procedure. The biopsy should be performed within 60 days prior to the planned first dose of study treatment.
  • Patients must have measurable disease per Response Evaluation Criteria In Solid Tumours (RECIST) 1.1.
  • World Health Organisation (WHO) performance status 0 or 1 with no deterioration between screening and the first dose of study treatment and a minimum life expectancy of 12 weeks.
  • Adequate coagulation parameters, defined as: International Normalisation Ratio (INR) <1.5 × ULN and activated partial thromboplastin time <1.5 × ULN unless patients are receiving therapeutic anti-coagulation which affects these parameters.
  • Patients with known tumour thrombus or deep vein thrombosis are eligible if clinically stable on low molecular weight heparin, factor Xa inhibitors or thrombin inhibitors for ≥2 weeks.
  • Willingness to adhere to the study treatment-specific contraception requirements.

Exclusion Criteria applicable to all study treatment modules (Groups A/B):

  • Patients whose disease has progressed within the first 3 months of osimertinib treatment
  • Patients must not have experienced a toxicity(-ies) that led to permanent discontinuation or dose reduction of prior osimertinib or have any unresolved toxicities from prior osimertinib treatment greater than CTCAE (Common Terminology Criteria for Adverse Event) Grade 1 at the time of starting study treatment
  • Patients should not have discontinued osimertinib >60 days prior to the first dose of study treatment
  • Prior or concurrent treatment with any systemic anti-cancer therapy for locally advanced/metastatic NSCLC including chemotherapy, biologic therapy, immunotherapy, or any investigational drug (exceptions do apply)
  • Major surgery within the 28 days prior to the first dose of study treatment except:

    o After minor surgery, at least 7 postoperative days must elapse before study treatment is initiated. After placement of vascular access, this waiting period is not required.

  • Receipt of live attenuated vaccine within 30 days prior to the first dose of study treatment.
  • Treatment with warfarin/coumarin analogues within 7 days prior to the first dose of study treatment
  • Diagnosis of small cell lung cancer (SCLC) or squamous cell carcinoma (SCC)
  • Spinal cord compression, symptomatic and unstable brain metastases, except for those patients who have completed definitive therapy, are not on steroids, have a stable neurologic status for at least 2 weeks after completion of the definitive therapy and steroids.
  • Allogenic organ transplantation
  • History of another primary malignancy except for:

    • Malignancy treated with curative intent and with no known active disease for at least 2 years before the first dose of study treatment.
    • Adequately treated nonmelanoma skin cancer or lentigo maligna without evidence of disease
    • Adequately treated carcinoma in situ without evidence of disease.
    • Localised non-invasive primary disease under surveillance.
  • Active infection, including infections with hepatitis B virus, hepatitis C virus, or human immunodeficiency virus
  • Pregnancy or breastfeeding in female patients
  • Any of the following cardiac criteria:

    • Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG
    • Unstable atrial fibrillation or unstable cardiac arrhythmia with a ventricular rate >100 bpm on an ECG at rest.
    • Uncontrolled hypertension
    • Uncontrolled angina or acute coronary syndrome within 6 months prior to screening.
    • At risk for brain perfusion problems or stroke, or transient ischemic attack in the last 6 months prior to screening
    • Symptomatic heart failure - prior or current cardiomyopathy.
    • Severe valvular heart disease
  • Inadequate bone marrow reserve or organ function
  • Creatinine clearance <50 mL/min, calculated by Cockcroft-Gault equation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03944772


Contacts
Layout table for location contacts
Contact: AstraZeneca Clinical Study Information Center 1-877-240-9479 information.center@astrazeneca.com
Contact: Cancer Study Locator (For US sites only) 1-877-400-4656 astrazeneca@emergingmed.com

  Hide Study Locations
Locations
Layout table for location information
United States, Arizona
Research Site Not yet recruiting
Scottsdale, Arizona, United States, 85258
United States, California
Research Site Not yet recruiting
Duarte, California, United States, 91010
Research Site Not yet recruiting
Los Angeles, California, United States, 90048
Research Site Not yet recruiting
Sacramento, California, United States, 95817
Research Site Not yet recruiting
Santa Rosa, California, United States, 95403
United States, Connecticut
Research Site Not yet recruiting
New Haven, Connecticut, United States, 06510
United States, Illinois
Research Site Not yet recruiting
Chicago, Illinois, United States, 60612
United States, Maryland
Research Site Not yet recruiting
Baltimore, Maryland, United States, 21287
United States, Massachusetts
Research Site Not yet recruiting
Boston, Massachusetts, United States, 02114
United States, New York
Research Site Not yet recruiting
New York, New York, United States, 10017
United States, Texas
Research Site Not yet recruiting
Houston, Texas, United States, 77030
United States, Washington
Research Site Not yet recruiting
Seattle, Washington, United States, 98195
Denmark
Research Site Not yet recruiting
Herlev, Denmark, 2730
Research Site Not yet recruiting
Odense C, Denmark, 5000
Research Site Not yet recruiting
Vejle, Denmark, 7100
Japan
Research Site Not yet recruiting
Chuo-ku, Japan, 104-0045
Research Site Recruiting
Fukuoka-shi, Japan, 812-8582
Research Site Not yet recruiting
Koto-ku, Japan, 135-8550
Research Site Not yet recruiting
Nagoya-shi, Japan, 464-8681
Research Site Not yet recruiting
Osaka-shi, Japan, 541-8567
Research Site Not yet recruiting
Wakayama-shi, Japan, 641-8510
Korea, Republic of
Research Site Not yet recruiting
Seongnam-si, Korea, Republic of, 13620
Research Site Not yet recruiting
Seoul, Korea, Republic of, 03722
Research Site Recruiting
Seoul, Korea, Republic of, 05505
Research Site Not yet recruiting
Seoul, Korea, Republic of, 06351
Netherlands
Research Site Not yet recruiting
Amsterdam, Netherlands, 1066 CX
Research Site Not yet recruiting
Amsterdam, Netherlands, 1081 HV
Research Site Not yet recruiting
Groningen, Netherlands, 9713 GZ
Research Site Not yet recruiting
Maastricht, Netherlands, 6229 HX
Research Site Not yet recruiting
Nijmegen, Netherlands, 6525 GA
Research Site Not yet recruiting
Rotterdam, Netherlands, 3015 GD
Norway
Research Site Not yet recruiting
Drammen, Norway, 3004
Research Site Not yet recruiting
Oslo, Norway, N-0310
Research Site Not yet recruiting
Trondheim, Norway, 7030
Spain
Research Site Not yet recruiting
A Coruña, Spain, 15006
Research Site Not yet recruiting
Barcelona, Spain, 08025
Research Site Not yet recruiting
Barcelona, Spain, 08036
Research Site Not yet recruiting
Madrid, Spain, 28041
Research Site Not yet recruiting
Madrid, Spain, 28046
Research Site Not yet recruiting
Sevilla, Spain, 41009
Sweden
Research Site Not yet recruiting
Stockholm, Sweden, 171 76
Sponsors and Collaborators
AstraZeneca
Investigators
Layout table for investigator information
Principal Investigator: Helena A Yu, MD Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA

Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT03944772     History of Changes
Other Study ID Numbers: D6186C00001
First Posted: May 10, 2019    Key Record Dates
Last Update Posted: July 10, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Keywords provided by AstraZeneca:
Non-small cell lung cancer
Phase II
Platform study
Biomarker-directed
Durvalumab
Osimertinib
Savolitinib
Gefitinib
Necitumumab
Platinum-containing doublet
Pemetrexed
Carboplatin
EGFR positive
NSCLC

Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Bronchial Neoplasms
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Carboplatin
Pemetrexed
Durvalumab
Gefitinib
Osimertinib
Necitumumab
Antibodies, Monoclonal
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors
Antineoplastic Agents, Immunological
Immunologic Factors
Physiological Effects of Drugs
Protein Kinase Inhibitors